Loading…
Reported covered position: Staff Assistant, Legislative Correspondent, Legislative Aide, Sen. Susan Collins (R-ME)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: SOLIDARITY HEALTHSHARE · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
S. 653/H.R. 2062: The Health Care Sharing Ministry Tax Parity Act; H.R. 1/OBBB budget reconciliation and possible reconciliation 2.0 opportunities; IRS issues pertaining to sharing ministries.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: SOLIDARITY HEALTHSHARE · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
SOLIDARITY HEALTHSHARE via FAEGRE DRINKER BIDDLE & REATH LLP
2025 · third_quarter · Q3
S. 653/H.R. 2062: The Health Care Sharing Ministry Tax Parity Act; H.R. 1/OBBB budget reconciliation and possible reconciliation 2.0 opportunities; IRS issues pertaining to sharing ministries.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WHOLESALE & SPECIALTY INSURANCE ASSOCIATION via FAEGRE DRINKER BIDDLE & REATH LLP
2025 · second_quarter · Q2
Source: Senate LDA
| SOLIDARITY HEALTHSHARE |
| 3 |
| 2025 |
| UNDERWRITERS LABORATORIES | 2 | 2023 |
| FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS | 1 | 2024 |
S. 653/H.R. 2062: The Health Care Sharing Ministry Tax Parity Act; H.R. 1/OBBB budget reconciliation
Food issues; Issues related to natural cheese; H.R. 1394/S.184, the Codifying Useful Regulatory Definitions Act (CURD) Act; House and Senate Agriculture Acts.
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.
To amend the Internal Revenue Code of 1986 to treat membership in a health care sharing ministry as a medical expense, and for other purposes.
Client: SOLIDARITY HEALTHSHARE · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
S. 653/H.R. 2062: The Health Care Sharing Ministry Tax Parity Act; H.R. 1/OBBB budget reconciliation and possible reconciliation 2.0 opportunities; IRS issues pertaining to sharing ministries.
To amend the Internal Revenue Code of 1986 to treat membership in a health care sharing ministry as a medical expense, and for other purposes.
Client: SOLIDARITY HEALTHSHARE · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
S. 653/H.R. 2062: The Health Care Sharing Ministry Tax Parity Act; budget reconciliation
To amend the Internal Revenue Code of 1986 to treat membership in a health care sharing ministry as a medical expense, and for other purposes.
Client: SOLIDARITY HEALTHSHARE · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
S. 653/H.R. 2062: The Health Care Sharing Ministry Tax Parity Act; H.R. 1/OBBB budget reconciliation
Insurance Data Protection Act
Client: WHOLESALE & SPECIALTY INSURANCE ASSOCIATION · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Issues related to extension of the National Flood Insurance Program; enactment of a safe harbor for insurers of state-legal cannabis businesses; Establishment of the National Association of Registered Agents & Brokers board; Issues related to establishing a safe harbor for insurance companies to provide services to state-legal cannabis operations; H.R. 3437/S. 1544, the Insurance Data Protection Act.
Stop STALLING Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.
Stop STALLING Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.
Stop STALLING Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.
Stop STALLING Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.
Preserve Access to Affordable Generics and Biosimilars Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.
Preserve Access to Affordable Generics and Biosimilars Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.
Preserve Access to Affordable Generics and Biosimilars Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.
Preserve Access to Affordable Generics and Biosimilars Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.
Interagency Patent Coordination and Improvement Act of 2025
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.
Interagency Patent Coordination and Improvement Act of 2025
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.
Interagency Patent Coordination and Improvement Act of 2025
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.
Interagency Patent Coordination and Improvement Act of 2025
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.
Insurance Data Protection Act
Client: WHOLESALE & SPECIALTY INSURANCE ASSOCIATION · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Issues related to extension of the National Flood Insurance Program; enactment of a safe harbor for insurers of state-legal cannabis businesses; Establishment of the National Association of Registered Agents & Brokers board; Issues related to establishing a safe harbor for insurance companies to provide services to state-legal cannabis operations; H.R. 3437/S. 1544, the Insurance Data Protection Act.
Food issues; Issues related to natural cheese; H.R. 1394/S.184, the Codifying Useful Regulatory Definitions Act (CURD) Act; House and Senate Agriculture Acts.
Skinny Labels, Big Savings Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.
Skinny Labels, Big Savings Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.
Skinny Labels, Big Savings Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.
Skinny Labels, Big Savings Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.
A bill to amend the Internal Revenue Code of 1986 to treat membership in a health care sharing ministry as a medical expense, and for other purposes.
Client: SOLIDARITY HEALTHSHARE · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
S. 653/H.R. 2062: The Health Care Sharing Ministry Tax Parity Act; H.R. 1/OBBB budget reconciliation and possible reconciliation 2.0 opportunities; IRS issues pertaining to sharing ministries.
A bill to amend the Internal Revenue Code of 1986 to treat membership in a health care sharing ministry as a medical expense, and for other purposes.
Client: SOLIDARITY HEALTHSHARE · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
S. 653/H.R. 2062: The Health Care Sharing Ministry Tax Parity Act; H.R. 1/OBBB budget reconciliation
A bill to amend the Internal Revenue Code of 1986 to treat membership in a health care sharing ministry as a medical expense, and for other purposes.
Client: SOLIDARITY HEALTHSHARE · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
S. 653/H.R. 2062: The Health Care Sharing Ministry Tax Parity Act; budget reconciliation
Drug Price Transparency in Medicaid Act of 2023
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Changes to Hatch-Waxman's 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378); Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S. 142), Affordable Prescriptions for Patients Act (S. 150); Block, Report, and Suspend Suspicious Shipments Act (H.R. 501); Proposal related to drug shortages.
Drug Price Transparency in Medicaid Act of 2023
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378). Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S.142), Affordable Prescriptions for Patients Act (S.150). Block, Report, and Suspend Suspicious Shipments Act (H.R. 501). Proposals related to drug shortages.
Drug Price Transparency in Medicaid Act of 2023
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378). Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S.142), Affordable Prescriptions for Patients Act (S.150). Block, Report, and Suspend Suspicious Shipments Act (H.R. 501). Proposals related to drug shortages.
Drug Price Transparency in Medicaid Act of 2023
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Changes to Hatch-Waxman's 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378); Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S. 142), Affordable Prescriptions for Patients Act (S. 150); Block, Report, and Suspend Suspicious Shipments Act (H.R. 501); Proposal related to drug shortages.
Food issues; issues related to natural cheese; H.R. 1803 / S. 981, the Codifying Useful Regulatory Definitions Act (CURD) Act; House and Senate Agriculture Acts.
Food issues; issues related to natural cheese; H.R. 1803 / S. 981, the Codifying Useful Regulatory Definitions Act (CURD) Act; House and Senate Agriculture Acts.
Food issues; issues related to natural cheese; H.R. 1803 / S. 981, the Codifying Useful Regulatory Definitions Act (CURD) Act; House and Senate Agriculture Acts.
Food issues; issues related to natural cheese; H.R. 1803 / S. 981, the Codifying Useful Regulatory Definitions Act (CURD) Act.
National Defense Authorization Act for Fiscal Year 2024
Client: IFB SOLUTIONS · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
S. 2226 / H.R. 2670, the National Defense Authorization Act (including the bill numbers to update the generic NDAA.
National Defense Authorization Act for Fiscal Year 2024
Client: IFB SOLUTIONS · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
S. 2226 / H.R. 2670, the National Defense Authorization Act (including the bill numbers to update the generic NDAA.
National Defense Authorization Act for Fiscal Year 2024
Client: IFB SOLUTIONS · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
S. 2226 / H.R. 2670, the National Defense Authorization Act (including the bill numbers to update the generic NDAA.
National Defense Authorization Act for Fiscal Year 2024
Client: IFB SOLUTIONS · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
S. 2226 / H.R. 2670, the National Defense Authorization Act (including the bill numbers to update the generic NDAA.
Block, Report, and Suspend Suspicious Shipments Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Changes to Hatch-Waxman's 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378); Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S. 142), Affordable Prescriptions for Patients Act (S. 150); Block, Report, and Suspend Suspicious Shipments Act (H.R. 501); Proposal related to drug shortages.
Block, Report, and Suspend Suspicious Shipments Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378). Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S.142), Affordable Prescriptions for Patients Act (S.150). Block, Report, and Suspend Suspicious Shipments Act (H.R. 501). Proposals related to drug shortages.
Block, Report, and Suspend Suspicious Shipments Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378). Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S.142), Affordable Prescriptions for Patients Act (S.150). Block, Report, and Suspend Suspicious Shipments Act (H.R. 501). Proposals related to drug shortages.
Block, Report, and Suspend Suspicious Shipments Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Changes to Hatch-Waxman's 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378); Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S. 142), Affordable Prescriptions for Patients Act (S. 150); Block, Report, and Suspend Suspicious Shipments Act (H.R. 501); Proposal related to drug shortages.
Lower Costs, More Transparency Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Changes to Hatch-Waxman's 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378); Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S. 142), Affordable Prescriptions for Patients Act (S. 150); Block, Report, and Suspend Suspicious Shipments Act (H.R. 501); Proposal related to drug shortages.
Lower Costs, More Transparency Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378). Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S.142), Affordable Prescriptions for Patients Act (S.150). Block, Report, and Suspend Suspicious Shipments Act (H.R. 501). Proposals related to drug shortages.
Lower Costs, More Transparency Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378). Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S.142), Affordable Prescriptions for Patients Act (S.150). Block, Report, and Suspend Suspicious Shipments Act (H.R. 501). Proposals related to drug shortages.
Lower Costs, More Transparency Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Changes to Hatch-Waxman's 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378); Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S. 142), Affordable Prescriptions for Patients Act (S. 150); Block, Report, and Suspend Suspicious Shipments Act (H.R. 501); Proposal related to drug shortages.
Prescription Pricing for the People Act of 2023
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378). Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S.142), Affordable Prescriptions for Patients Act (S.150). Block, Report, and Suspend Suspicious Shipments Act (H.R. 501). Proposals related to drug shortages.
Prescription Pricing for the People Act of 2023
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Changes to Hatch-Waxman's 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378); Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S. 142), Affordable Prescriptions for Patients Act (S. 150); Block, Report, and Suspend Suspicious Shipments Act (H.R. 501); Proposal related to drug shortages.
Prescription Pricing for the People Act of 2023
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Changes to Hatch-Waxman's 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378); Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S. 142), Affordable Prescriptions for Patients Act (S. 150); Block, Report, and Suspend Suspicious Shipments Act (H.R. 501); Proposal related to drug shortages.
Prescription Pricing for the People Act of 2023
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378). Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S.142), Affordable Prescriptions for Patients Act (S.150). Block, Report, and Suspend Suspicious Shipments Act (H.R. 501). Proposals related to drug shortages.
Pharmacy Benefit Manager Transparency Act of 2023
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378). Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S.142), Affordable Prescriptions for Patients Act (S.150). Block, Report, and Suspend Suspicious Shipments Act (H.R. 501). Proposals related to drug shortages.
Pharmacy Benefit Manager Transparency Act of 2023
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378). Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S.142), Affordable Prescriptions for Patients Act (S.150). Block, Report, and Suspend Suspicious Shipments Act (H.R. 501). Proposals related to drug shortages.
Pharmacy Benefit Manager Transparency Act of 2023
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Changes to Hatch-Waxman's 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378); Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S. 142), Affordable Prescriptions for Patients Act (S. 150); Block, Report, and Suspend Suspicious Shipments Act (H.R. 501); Proposal related to drug shortages.
Pharmacy Benefit Manager Transparency Act of 2023
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Changes to Hatch-Waxman's 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378); Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S. 142), Affordable Prescriptions for Patients Act (S. 150); Block, Report, and Suspend Suspicious Shipments Act (H.R. 501); Proposal related to drug shortages.
Preserve Access to Affordable Generics and Biosimilars Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Changes to Hatch-Waxman's 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378); Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S. 142), Affordable Prescriptions for Patients Act (S. 150); Block, Report, and Suspend Suspicious Shipments Act (H.R. 501); Proposal related to drug shortages.
Preserve Access to Affordable Generics and Biosimilars Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378). Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S.142), Affordable Prescriptions for Patients Act (S.150). Block, Report, and Suspend Suspicious Shipments Act (H.R. 501). Proposals related to drug shortages.
Preserve Access to Affordable Generics and Biosimilars Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378). Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S.142), Affordable Prescriptions for Patients Act (S.150). Block, Report, and Suspend Suspicious Shipments Act (H.R. 501). Proposals related to drug shortages.
Preserve Access to Affordable Generics and Biosimilars Act
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Changes to Hatch-Waxman's 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378); Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S. 142), Affordable Prescriptions for Patients Act (S. 150); Block, Report, and Suspend Suspicious Shipments Act (H.R. 501); Proposal related to drug shortages.
Affordable Prescriptions for Patients Act of 2023
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Changes to Hatch-Waxman's 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378); Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S. 142), Affordable Prescriptions for Patients Act (S. 150); Block, Report, and Suspend Suspicious Shipments Act (H.R. 501); Proposal related to drug shortages.
Affordable Prescriptions for Patients Act of 2023
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Changes to Hatch-Waxman's 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378); Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S. 142), Affordable Prescriptions for Patients Act (S. 150); Block, Report, and Suspend Suspicious Shipments Act (H.R. 501); Proposal related to drug shortages.
Affordable Prescriptions for Patients Act of 2023
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378). Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S.142), Affordable Prescriptions for Patients Act (S.150). Block, Report, and Suspend Suspicious Shipments Act (H.R. 501). Proposals related to drug shortages.
Affordable Prescriptions for Patients Act of 2023
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378). Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S.142), Affordable Prescriptions for Patients Act (S.150). Block, Report, and Suspend Suspicious Shipments Act (H.R. 501). Proposals related to drug shortages.
Block Grant Assistance Act of 2023
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Changes to Hatch-Waxman's 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378); Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S. 142), Affordable Prescriptions for Patients Act (S. 150); Block, Report, and Suspend Suspicious Shipments Act (H.R. 501); Proposal related to drug shortages.
Block Grant Assistance Act of 2023
Client: TEVA PHARMACEUTICALS USA, INC. · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Changes to Hatch-Waxman's 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378); Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S. 142), Affordable Prescriptions for Patients Act (S. 150); Block, Report, and Suspend Suspicious Shipments Act (H.R. 501); Proposal related to drug shortages.
National Defense Authorization Act for Fiscal Year 2024
Client: IFB SOLUTIONS · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
S. 2226 / H.R. 2670, the National Defense Authorization Act (including the bill numbers to update the generic NDAA.
National Defense Authorization Act for Fiscal Year 2024
Client: IFB SOLUTIONS · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
S. 2226 / H.R. 2670, the National Defense Authorization Act (including the bill numbers to update the generic NDAA.
National Defense Authorization Act for Fiscal Year 2024
Client: IFB SOLUTIONS · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
S. 2226 / H.R. 2670, the National Defense Authorization Act (including the bill numbers to update the generic NDAA.
National Defense Authorization Act for Fiscal Year 2024
Client: IFB SOLUTIONS · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
S. 2226 / H.R. 2670, the National Defense Authorization Act (including the bill numbers to update the generic NDAA.
SAFER Banking Act
Client: WHOLESALE & SPECIALTY INSURANCE ASSOCIATION · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Issues related to extension of the National Flood Insurance Program; enactment of a safe harbor for insurers of state-legal cannabis businesses; Establishment of the National Association of Registered Agents & Brokers board; issues related to S. 2860, the SAFER Banking Act.
SAFER Banking Act
Client: WHOLESALE & SPECIALTY INSURANCE ASSOCIATION · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Issues related to extension of the National Flood Insurance Program; enactment of a safe harbor for insurers of state-legal cannabis businesses; Establishment of the National Association of Registered Agents & Brokers board; issues related to S. 2860, the SAFER Banking Act.
SAFER Banking Act
Client: WHOLESALE & SPECIALTY INSURANCE ASSOCIATION · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Issues related to extension of the National Flood Insurance Program; enactment of a safe harbor for insurers of state-legal cannabis businesses; Establishment of the National Association of Registered Agents & Brokers board; issues related to S. 2860, the SAFER Banking Act.
SAFER Banking Act
Client: WHOLESALE & SPECIALTY INSURANCE ASSOCIATION · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Issues related to extension of the National Flood Insurance Program; enactment of a safe harbor for insurers of state-legal cannabis businesses; Establishment of the National Association of Registered Agents & Brokers board; issues related to S. 2860, the SAFER Banking Act.
Food issues; issues related to natural cheese; H.R. 1803 / S. 981, the Codifying Useful Regulatory Definitions Act (CURD) Act; House and Senate Agriculture Acts.
Food issues; issues related to natural cheese; H.R. 1803 / S. 981, the Codifying Useful Regulatory Definitions Act (CURD) Act; House and Senate Agriculture Acts.
Food issues; issues related to natural cheese; H.R. 1803 / S. 981, the Codifying Useful Regulatory Definitions Act (CURD) Act.
Food issues; issues related to natural cheese; H.R. 1803 / S. 981, the Codifying Useful Regulatory Definitions Act (CURD) Act; House and Senate Agriculture Acts.
Food issues; issues related to natural cheese; H.R. 1803 / S. 981, the Codifying Useful Regulatory Definitions Act (CURD) Act.
Food issues; issues related to natural cheese; H.R. 1803 / S. 981, the Codifying Useful Regulatory Definitions Act (CURD) Act.
Food issues; issues related to natural cheese; H.R. 1803 / S. 981, the Codifying Useful Regulatory Definitions Act (CURD) Act.
National Defense Authorization Act for Fiscal Year 2024
Client: DMG MORI FEDERAL SERVICES · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
S. 2226 / H.R. 2670, the National Defense Authorization Act
National Defense Authorization Act for Fiscal Year 2024
Client: DMG MORI FEDERAL SERVICES · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
S. 2226 / H.R. 2670, the National Defense Authorization Act
National Defense Authorization Act for Fiscal Year 2024
Client: IFB SOLUTIONS · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
S. 2226 / H.R. 2670, the National Defense Authorization Act (including the bill numbers to update the generic NDAA.
National Defense Authorization Act for Fiscal Year 2024
Client: DMG MORI FEDERAL SERVICES · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
S. 2226 / H.R. 2670, the National Defense Authorization Act
National Defense Authorization Act for Fiscal Year 2024
Client: IFB SOLUTIONS · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
S. 2226 / H.R. 2670, the National Defense Authorization Act (including the bill numbers to update the generic NDAA.
National Defense Authorization Act for Fiscal Year 2024
Client: DMG MORI FEDERAL SERVICES · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
S. 2226 / H.R. 2670, the National Defense Authorization Act
SAFER Banking Act
Client: WHOLESALE & SPECIALTY INSURANCE ASSOCIATION · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Issues related to extension of the National Flood Insurance Program; enactment of a safe harbor for insurers of state-legal cannabis businesses; Establishment of the National Association of Registered Agents & Brokers board; issues related to S. 2860, the SAFER Banking Act.
SAFER Banking Act
Client: WHOLESALE & SPECIALTY INSURANCE ASSOCIATION · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Issues related to extension of the National Flood Insurance Program; enactment of a safe harbor for insurers of state-legal cannabis businesses; Establishment of the National Association of Registered Agents & Brokers board; issues related to S. 2860, the SAFER Banking Act.
SAFER Banking Act
Client: WHOLESALE & SPECIALTY INSURANCE ASSOCIATION · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Issues related to extension of the National Flood Insurance Program; enactment of a safe harbor for insurers of state-legal cannabis businesses; Establishment of the National Association of Registered Agents & Brokers board; issues related to S. 2860, the SAFER Banking Act.
SAFER Banking Act
Client: WHOLESALE & SPECIALTY INSURANCE ASSOCIATION · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Issues related to extension of the National Flood Insurance Program; enactment of a safe harbor for insurers of state-legal cannabis businesses; Establishment of the National Association of Registered Agents & Brokers board; issues related to S. 2860, the SAFER Banking Act.
Food issues; issues related to natural cheese; H.R. 1803 / S. 981, the Codifying Useful Regulatory Definitions Act (CURD) Act.
Food issues; issues related to natural cheese; H.R. 1803 / S. 981, the Codifying Useful Regulatory Definitions Act (CURD) Act.
Food issues; issues related to natural cheese; H.R. 1803 / S. 981, the Codifying Useful Regulatory Definitions Act (CURD) Act.
Issues related to extension of the National Flood Insurance Program; enactment of a safe harbor for insurers of state-legal cannabis businesses; Establishment of the National Association of Registered Agents & Brokers board; Issues related to establishing a safe harbor for insurance companies to provide services to state-legal cannabis operations; H.R. 3437/S. 1544, the Insurance Data Protection Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IFB SOLUTIONS via FAEGRE DRINKER BIDDLE & REATH LLP
2025 · second_quarter · Q2
Issues related to AbilityOne program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TEVA PHARMACEUTICALS USA, INC. via FAEGRE DRINKER BIDDLE & REATH LLP
2025 · second_quarter · Q2
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SOLIDARITY HEALTHSHARE via FAEGRE DRINKER BIDDLE & REATH LLP
2025 · second_quarter · Q2
S. 653/H.R. 2062: The Health Care Sharing Ministry Tax Parity Act; H.R. 1/OBBB budget reconciliation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ILLINOIS INSTITUTE OF TECHNOLOGY (ILLINOIS TECH) via FAEGRE DRINKER BIDDLE & REATH LLP
2025 · second_quarter · Q2
Advocacy on all government relations matter, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
Advocacy on all government relations matter, including Congressionally-Directed Spending requests, the National Center for Advanced Manufactuing, and other education policy matters.
Advocacy on all government relations matter, including Congressionally-Directed Spending requests, the National Center for Advanced Manufactuing, and other education policy matters.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DMG MORI FEDERAL SERVICES via FAEGRE DRINKER BIDDLE & REATH LLP
2025 · second_quarter · Q2
House and Senate National Defense Authorization Acts; the National Defense Authorization Act.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
WHOLESALE & SPECIALTY INSURANCE ASSOCIATION via FAEGRE DRINKER BIDDLE & REATH LLP
2025 · first_quarter · Q1
Issues related to extension of the National Flood Insurance Program; enactment of a safe harbor for insurers of state-legal cannabis businesses; Establishment of the National Association of Registered Agents & Brokers board; Issues related to establishing a safe harbor for insurance companies to provide services to state-legal cannabis operations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TEVA PHARMACEUTICALS USA, INC. via FAEGRE DRINKER BIDDLE & REATH LLP
2025 · first_quarter · Q1
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ILLINOIS INSTITUTE OF TECHNOLOGY (ILLINOIS TECH) via FAEGRE DRINKER BIDDLE & REATH LLP
2025 · first_quarter · Q1
Advocacy on all government relations matter, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
Advocacy on all government relations matter, including Congressionally-Directed Spending requests, the National Center for Advanced Manufactuing, and other education policy matters.
Advocacy on all government relations matter, including Congressionally-Directed Spending requests, the National Center for Advanced Manufactuing, and other education policy matters.
SARGENTO FOODS INC. via FAEGRE DRINKER BIDDLE & REATH LLP
2025 · first_quarter · Q1
Food issues; Issues related to natural cheese; H.R. 1394/S.184, the Codifying Useful Regulatory Definitions Act (CURD) Act; House and Senate Agriculture Acts.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DMG MORI FEDERAL SERVICES via FAEGRE DRINKER BIDDLE & REATH LLP
2025 · first_quarter · Q1
House and Senate National Defense Authorization Acts; the National Defense Authorization Act.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
SOLIDARITY HEALTHSHARE via FAEGRE DRINKER BIDDLE & REATH LLP
2025 · first_quarter · Q1
S. 653/H.R. 2062: The Health Care Sharing Ministry Tax Parity Act; budget reconciliation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TEVA PHARMACEUTICALS USA, INC. via FAEGRE DRINKER BIDDLE & REATH LLP
2024 · fourth_quarter · Q4
Changes to Hatch-Waxman's 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378); Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S. 142), Affordable Prescriptions for Patients Act (S. 150); Block, Report, and Suspend Suspicious Shipments Act (H.R. 501); Proposal related to drug shortages.
Changes to Hatch-Waxman's 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378); Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S. 142), Affordable Prescriptions for Patients Act (S. 150); Block, Report, and Suspend Suspicious Shipments Act (H.R. 501); Proposal related to drug shortages.
IFB SOLUTIONS via FAEGRE DRINKER BIDDLE & REATH LLP
2024 · fourth_quarter · Q4
S. 2226 / H.R. 2670, the National Defense Authorization Act (including the bill numbers to update the generic NDAA.
Issues related to the AbilityOne program; National Defense Authorization Act.
Issues related to the AbilityOne program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ILLINOIS INSTITUTE OF TECHNOLOGY (ILLINOIS TECH) via FAEGRE DRINKER BIDDLE & REATH LLP
2024 · fourth_quarter · 4A
Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
Advocacy on all government relations matter, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
Advocacy on all government relations matter, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
ILLINOIS INSTITUTE OF TECHNOLOGY (ILLINOIS TECH) via FAEGRE DRINKER BIDDLE & REATH LLP
2024 · fourth_quarter · Q4
Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
Advocacy on all government relations matter, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
Advocacy on all government relations matter, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
DMG MORI FEDERAL SERVICES via FAEGRE DRINKER BIDDLE & REATH LLP
2024 · fourth_quarter · Q4
House and Senate National Defense Authorization Acts; the National Defense Authorization Act
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
SARGENTO FOODS INC. via FAEGRE DRINKER BIDDLE & REATH LLP
2024 · fourth_quarter · Q4
Food issues; issues related to natural cheese; H.R. 1803 / S. 981, the Codifying Useful Regulatory Definitions Act (CURD) Act; House and Senate Agriculture Acts.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WHOLESALE & SPECIALTY INSURANCE ASSOCIATION via FAEGRE DRINKER BIDDLE & REATH LLP
2024 · fourth_quarter · Q4
Issues related to extension of the National Flood Insurance Program; enactment of a safe harbor for insurers of state-legal cannabis businesses; Establishment of the National Association of Registered Agents & Brokers board; issues related to S. 2860, the SAFER Banking Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WHOLESALE & SPECIALTY INSURANCE ASSOCIATION via FAEGRE DRINKER BIDDLE & REATH LLP
2024 · third_quarter · Q3
Issues related to extension of the National Flood Insurance Program; enactment of a safe harbor for insurers of state-legal cannabis businesses; Establishment of the National Association of Registered Agents & Brokers board; issues related to S. 2860, the SAFER Banking Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, White House Office
SARGENTO FOODS INC. via FAEGRE DRINKER BIDDLE & REATH LLP
2024 · third_quarter · Q3
Food issues; issues related to natural cheese; H.R. 1803 / S. 981, the Codifying Useful Regulatory Definitions Act (CURD) Act; House and Senate Agriculture Acts.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ILLINOIS INSTITUTE OF TECHNOLOGY (ILLINOIS TECH) via FAEGRE DRINKER BIDDLE & REATH LLP
2024 · third_quarter · Q3
Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
IFB SOLUTIONS via FAEGRE DRINKER BIDDLE & REATH LLP
2024 · third_quarter · Q3
Issues related to the AbilityOne program; National Defense Authorization Act.
S. 2226 / H.R. 2670, the National Defense Authorization Act (including the bill numbers to update the generic NDAA.
Issues related to the AbilityOne program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DMG MORI FEDERAL SERVICES via FAEGRE DRINKER BIDDLE & REATH LLP
2024 · third_quarter · Q3
House and Senate National Defense Authorization Acts; the National Defense Authorization Act
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
TEVA PHARMACEUTICALS USA, INC. via FAEGRE DRINKER BIDDLE & REATH LLP
2024 · second_quarter · RR
Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378). Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S.142), Affordable Prescriptions for Patients Act (S.150). Block, Report, and Suspend Suspicious Shipments Act (H.R. 501). Proposals related to drug shortages.
Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378). Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S.142), Affordable Prescriptions for Patients Act (S.150). Block, Report, and Suspend Suspicious Shipments Act (H.R. 501). Proposals related to drug shortages.
WHOLESALE & SPECIALTY INSURANCE ASSOCIATION via FAEGRE DRINKER BIDDLE & REATH LLP
2024 · second_quarter · Q2
Issues related to extension of the National Flood Insurance Program; enactment of a safe harbor for insurers of state-legal cannabis businesses; Establishment of the National Association of Registered Agents & Brokers board; issues related to S. 2860, the SAFER Banking Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, White House Office
ILLINOIS INSTITUTE OF TECHNOLOGY (ILLINOIS TECH) via FAEGRE DRINKER BIDDLE & REATH LLP
2024 · second_quarter · Q2
Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
SARGENTO FOODS INC. via FAEGRE DRINKER BIDDLE & REATH LLP
2024 · second_quarter · Q2
Food issues; issues related to natural cheese; H.R. 1803 / S. 981, the Codifying Useful Regulatory Definitions Act (CURD) Act; House and Senate Agriculture Acts.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IFB SOLUTIONS via FAEGRE DRINKER BIDDLE & REATH LLP
2024 · second_quarter · Q2
S. 2226 / H.R. 2670, the National Defense Authorization Act (including the bill numbers to update the generic NDAA.
Issues related to the AbilityOne program.
Issues related to the AbilityOne program; National Defense Authorization Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ILLINOIS INSTITUTE OF TECHNOLOGY (ILLINOIS TECH) via FAEGRE DRINKER BIDDLE & REATH LLP
2024 · first_quarter · 1A
Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
DMG MORI FEDERAL SERVICES via FAEGRE DRINKER BIDDLE & REATH LLP
2024 · first_quarter · Q1
House and Senate National Defense Authorization Acts; the National Defense Authorization Act
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
SARGENTO FOODS INC. via FAEGRE DRINKER BIDDLE & REATH LLP
2024 · first_quarter · Q1
Food issues; issues related to natural cheese; H.R. 1803 / S. 981, the Codifying Useful Regulatory Definitions Act (CURD) Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ILLINOIS INSTITUTE OF TECHNOLOGY (ILLINOIS TECH) via FAEGRE DRINKER BIDDLE & REATH LLP
2024 · first_quarter · Q1
Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
WHOLESALE & SPECIALTY INSURANCE ASSOCIATION via FAEGRE DRINKER BIDDLE & REATH LLP
2024 · first_quarter · Q1
Issues related to extension of the National Flood Insurance Program; enactment of a safe harbor for insurers of state-legal cannabis businesses; Establishment of the National Association of Registered Agents & Brokers board; issues related to S. 2860, the SAFER Banking Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
IFB SOLUTIONS via FAEGRE DRINKER BIDDLE & REATH LLP
2024 · first_quarter · Q1
S. 2226 / H.R. 2670, the National Defense Authorization Act (including the bill numbers to update the generic NDAA.
Issues related to the AbilityOne program; National Defense Authorization Act.
Issues related to the AbilityOne program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS via FAEGRE DRINKER BIDDLE & REATH LLP
2024 · first_quarter · RR
Research funding and therapy development.
WHOLESALE & SPECIALTY INSURANCE ASSOCIATION via FAEGRE DRINKER BIDDLE & REATH LLP
2023 · fourth_quarter · 4A
Issues related to extension of the National Flood Insurance Program; enactment of a safe harbor for insurers of state-legal cannabis businesses; Establishment of the National Association of Registered Agents & Brokers board; issues related to S. 2860, the SAFER Banking Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
DMG MORI FEDERAL SERVICES via FAEGRE DRINKER BIDDLE & REATH LLP
2023 · fourth_quarter · Q4
S. 2226 / H.R. 2670, the National Defense Authorization Act
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
WHOLESALE & SPECIALTY INSURANCE ASSOCIATION via FAEGRE DRINKER BIDDLE & REATH LLP
2023 · fourth_quarter · 4A
Issues related to extension of the National Flood Insurance Program; enactment of a safe harbor for insurers of state-legal cannabis businesses; Establishment of the National Association of Registered Agents & Brokers board; issues related to S. 2860, the SAFER Banking Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
SARGENTO FOODS INC. via FAEGRE DRINKER BIDDLE & REATH LLP
2023 · fourth_quarter · Q4
Food issues; issues related to natural cheese; H.R. 1803 / S. 981, the Codifying Useful Regulatory Definitions Act (CURD) Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IFB SOLUTIONS via FAEGRE DRINKER BIDDLE & REATH LLP
2023 · fourth_quarter · Q4
S. 2226 / H.R. 2670, the National Defense Authorization Act (including the bill numbers to update the generic NDAA.
Issues related to the AbilityOne program.
Issues related to the AbilityOne program; National Defense Authorization Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WHOLESALE & SPECIALTY INSURANCE ASSOCIATION via FAEGRE DRINKER BIDDLE & REATH LLP
2023 · fourth_quarter · Q4
Issues related to extension of the National Flood Insurance Program; enactment of a safe harbor for insurers of state-legal cannabis businesses; Establishment of the National Association of Registered Agents & Brokers board; issues related to S. 2860, the SAFER Banking Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
ILLINOIS INSTITUTE OF TECHNOLOGY (ILLINOIS TECH) via FAEGRE DRINKER BIDDLE & REATH LLP
2023 · fourth_quarter · Q4
Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
ILLINOIS INSTITUTE OF TECHNOLOGY (ILLINOIS TECH) via FAEGRE DRINKER BIDDLE & REATH LLP
2023 · third_quarter · Q3
Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
WHOLESALE & SPECIALTY INSURANCE ASSOCIATION via FAEGRE DRINKER BIDDLE & REATH LLP
2023 · third_quarter · Q3
Issues related to extension of the National Flood Insurance Program; enactment of a safe harbor for insurers of state-legal cannabis businesses; Establishment of the National Association of Registered Agents & Brokers board; issues related to S. 2860, the SAFER Banking Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
DMG MORI FEDERAL SERVICES via FAEGRE DRINKER BIDDLE & REATH LLP
2023 · third_quarter · Q3
S. 2226 / H.R. 2670, the National Defense Authorization Act
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
SARGENTO FOODS INC. via FAEGRE DRINKER BIDDLE & REATH LLP
2023 · third_quarter · Q3
Food issues; issues related to natural cheese; H.R. 1803 / S. 981, the Codifying Useful Regulatory Definitions Act (CURD) Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ILLINOIS INSTITUTE OF TECHNOLOGY (ILLINOIS TECH) via FAEGRE DRINKER BIDDLE & REATH LLP
2023 · second_quarter · Q2
Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
DMG MORI FEDERAL SERVICES via FAEGRE DRINKER BIDDLE & REATH LLP
2023 · second_quarter · Q2
Issues related to advanced and additive manufacturing; appropriations; National Defense Authorization Act.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
UNDERWRITERS LABORATORIES via FAEGRE DRINKER BIDDLE & REATH LLP
2023 · second_quarter · 2T
Implementation of bipartisan infrastructure.
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
SARGENTO FOODS INC. via FAEGRE DRINKER BIDDLE & REATH LLP
2023 · second_quarter · Q2
Food issues; issues related to natural cheese; H.R. 1803 / S. 981, the Codifying Useful Regulatory Definitions Act (CURD) Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WHOLESALE & SPECIALTY INSURANCE ASSOCIATION via FAEGRE DRINKER BIDDLE & REATH LLP
2023 · second_quarter · Q2
Issues related to extension of the National Flood Insurance Program; enactment of a safe harbor for insurers of state-legal cannabis businesses; Establishment of the National Association of Registered Agents & Brokers board.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
DMG MORI FEDERAL SERVICES via FAEGRE DRINKER BIDDLE & REATH LLP
2023 · first_quarter · Q1
Issues related to advanced and additive manufacturing; appropriations; National Defense Authorization Act.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
UNDERWRITERS LABORATORIES via FAEGRE DRINKER BIDDLE & REATH LLP
2023 · first_quarter · Q1
Implementation of bipartisan infrastructure.
Filing targets: Energy, Dept of, Transportation, Dept of (DOT)
SARGENTO FOODS INC. via FAEGRE DRINKER BIDDLE & REATH LLP
2023 · first_quarter · Q1
Food issues; issues related to natural cheese.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WHOLESALE & SPECIALTY INSURANCE ASSOCIATION via FAEGRE DRINKER BIDDLE & REATH LLP
2023 · first_quarter · Q1
Issues related to extension of the National Flood Insurance Program; enactment of a safe harbor for insurers of state-legal cannabis businesses.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
ILLINOIS INSTITUTE OF TECHNOLOGY (ILLINOIS TECH) via FAEGRE DRINKER BIDDLE & REATH LLP
2023 · first_quarter · Q1
Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
ILLINOIS INSTITUTE OF TECHNOLOGY (ILLINOIS TECH) via FAEGRE DRINKER BIDDLE & REATH LLP
2023 · first_quarter · RR
Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.